🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Denmark / NCT03299478
Active, not recruiting Observational

Clinical Implementation of TNM-immunoscore in Resected Non-small Cell Lung Cancer

NCT03299478 · tracked via the Priya Life Science Denmark tracker
Phase
Observational
Started
2016-11-28
Last updated
2024-06-11

Condition(s) studied

Non-Small Cell Lung Cancer

Investigational drug(s) / intervention(s)

Will look for immune infiltration

Study summary

The purpose of this study is to validate TNM-Immunoscore in resected non-small cell lung cancer.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * resectable NSCLC * Age 18 and above * no other malignancy last 5 years * informed consent Exclusion Criteria: * multiple tumor foci * preoperative chemo- or radiotherapy * non-NSCLC histology * no tissue available for study * metastasis

Primary outcome measure(s)

Trial sites (5)

FacilityCityRegionStatus
Rigshospitalet Copenhagen København Ø
Odense Universitetshospital Odense Denmark
Oslo University Hospital Oslo Norway
University Hospital of North Norway Tromsø Norway
St.Olav Hospital, University Hospital of Trondheim Trondheim Norway

More University Hospital of North Norway trials in Denmark

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03299478 on ClinicalTrials.gov ↗ ← All trials in Denmark